相关产品推荐更多 >

Hemagglutinin/HA重组蛋白|Recombinant H1N1 HA-specific B cell probe(Y108F,AVI & His Tag)
¥4520
Coronavirus Nucleocapsid重组蛋白|Recombinant SARS-CoV-2 (2019-nCoV) Nucleocapsid-His Recombinant Protein
¥4500
CoV 3CLpro / 3C-like protease重组蛋白|重组新冠病毒冠状病毒3C样蛋白酶蛋白
¥4500
HIV Gag-p24重组蛋白|Recombinant HIV 1 (CRF08_BC) Gag-p24 Protein(His Tag)
¥4520
E154K/L452R/E484Q/D614G/P681R-新冠突变体重组蛋白
¥4500
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件:
-20℃ 至 -80℃
- 保质期:
12个月
- 英文名:
Influenza A H5N1 (A/bar-headed goose/Qinghai/14/2008) Hemagglutinin / HA Protein (His Tag)
- 库存:
99
- 供应商:
北京义翘神州科技股份有限公司
- 规格:
100 µg
蛋白名称:Hemagglutinin/HA蛋白, Hemagglutinin/HA protein
蛋白构建:A DNA sequence encoding the extracellular domain of Influenza A virus (A/bar-headed goose/Qinghai/14/2008 (H5N1)) (ACL28277.1) HA (Met 1-Gln 531) with cleavage site mutated (RERRRKKR → TETR, HA1+HA2, uncleaved) was expressed with a C-terminal polyhistidine tag.
表达宿主:HEK293 Cells
蛋白纯度:> 95 % as determined by SDS-PAGE
蛋白活性:0
蛋白内毒素:< 1.0 EU per μg of the protein as determined by the LAL method
预测N端:Asp 17
蛋白分子量:The secreted recombinant hemagglutinin of Influenza A virus H5N1 (A/bar-headed goose/Qinghai/14/2008) comprises 522 amino acids with the predicted molecular mass of 59.5 kDa. As a result of glycosylation, it migrates as an approximately 70 kDa band in Non-reduced SDS-PAGE and also exists as polymers.
蛋白NP号:ACL28277.1
蛋白氨基酸序列:Met1-Gln531
蛋白标签:C-His
蛋白保存条件:Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验The Mouse as Model System to Study Host‐Pathogen Interactions in Influenza A Infections
. Gambotto, A., Barratt‐Boyes, S.M., de Jong, M.D., Neumann, G., and Kawaoka, Y. 2008. Human infection with highly pathogenic H5N1 influenza virus. Lancet 371:1464‐1475.
全球人禽流感疫情统计(中文 ) 世界卫生组织报告全球人禽流感疫情统计(英文 ) 疫苗研究 编辑本段 回目录 2008年 澳大利亚宣布研制出禽流感疫苗 澳大利亚卫生部长尼古拉·罗克森6月17日宣布,澳已经研制出一种对付禽流感的人体疫苗。罗克森在堪培拉举行的记者招待会上说,这种疫苗由澳大利亚药物和疫苗制造公司CSL研制,是澳首次研制成功的针对禽流感的疫苗。这种疫苗可以预防在亚洲、中东、欧洲和非洲流行的H5N1
技术资料暂无技术资料 索取技术资料





